Listen to this podcast where Dr. Sadiq discusses: Intrathecal Methotrexate: A Treatment Options for Patients with Progressive Multiple Sclerosis.


Here, Armistead Williams, III, MD, speaks directly to neurologists about the hard questions that need to be addressed about this complex illness.  


The IMSMP is open.  If you are unable to keep any of your upcoming scheduled appointments, please contact the center directly at (212) 265-8070.  Thank you.


Due to loss of power from Hurricane Sandy, the IMSMP is closed today, October 30th.  We plan on re-opening as soon as possible.  We apologize for any inconvenience.


The IMSMP requests any patient who has appointments scheduled for tomorrow, Tuesday, October 30th to please call the center by 3pm today.  We would like to confirm you plan on keeping this appointment.  The IMSMP will close at 3pm today.  Please stay safe as the storm approaches.


Please check out the slideshow seen at the 15th Annual MSRCNY Patient Symposium.  Photos by Alden Reiss.


We look forward to seeing you at the Hilton New York this Sunday!


The IMSMP will be closing early at 1:30pm today. The offices and infusion suite will remain closed through the weekend and on Labor Day, Monday, September 3rd. We will re-open on Tuesday, September 4th. We would like to wish everyone a happy and safe holiday weekend!


The social work department is pleased to offer a second Spouses’ and Partners’ Support Group because of the popularity and demand for a forum in which spouses/partners of people with MS can share experiences and support each other.  

We are also seeking more participants for the following support groups:

· Professional Men’s Group - men who are working despite physical impairment.

· Newly Diagnosed Group - people who have been diagnosed with MS in the last 3 years....


By:  Dr. Armistead D.  Williams

A lot of our patients have asked about the recent study in the Journal of the American Medical Association that reports that beta interferons do not prevent disability.

Here’s our take:

This study has two important flaws. The first is that it compared people who took an interferon against a group of people who chose not to take interferon. This comparison group had mild MS for almost twice as long as the interferon group (5.6 versus 3...




Because you deserve only the best in MS healthcare. Experience the difference.

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.